NCT03701282 2026-03-18
Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 3 Active not recruiting
Clinical Trials
24 trialsNCT03462719 2026-03-12
GLOW
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT03336333 2026-03-09
SEQUOIA
BeOne Medicines
Phase 3 Active not recruiting
NCT03844048 2026-03-06
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
AbbVie
Phase 3 Active not recruiting
NCT04623541 2026-03-04
EPCOREâ„¢ CLL-1
Genmab
Phase 1/2 Active not recruiting
NCT06073821 2026-03-04
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
BeOne Medicines
Phase 3 Active not recruiting
NCT05650723 2026-02-25
Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab
Weill Medical College of Cornell University
Phase 2 Active not recruiting
NCT06524375 2026-02-25
BRAVE
Genentech, Inc.
Phase 2 Active not recruiting
NCT02756897 2026-02-19
Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05057494 2026-02-18
MAJIC
AstraZeneca
Phase 3 Active not recruiting
NCT02846623 2026-02-17
Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03580928 2026-02-13
AVO
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT05677919 2026-02-12
Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia
Mayo Clinic
Phase 2 Active not recruiting
NCT03513562 2026-02-06
Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations
Ohio State University Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT04419519 2026-01-29
Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT04965493 2026-01-29
BRUIN CLL-322
Eli Lilly and Company
Phase 3 Active not recruiting
NCT02427451 2026-01-27
Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia
Ohio State University Comprehensive Cancer Center
Phase 1/2 Active not recruiting
NCT04843904 2026-01-07
SAVE
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT03467867 2025-12-24
A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL
Georgetown University
Phase 2 Active not recruiting
NCT04447768 2025-10-14
The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT04501939 2025-09-02
Venetoclax
University of California, San Diego
Phase 2 Active not recruiting
NCT03534323 2025-08-14
Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS
Dana-Farber Cancer Institute
Phase 1/2 Active not recruiting
NCT03836261 2024-12-27
AMPLIFY
Acerta Pharma BV
Phase 3 Active not recruiting
NCT03422393 2024-07-05
Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib
University of California, San Diego
Phase 1 Active not recruiting